Shubhajit Paul, a senior research fellow in Boehringer Ingelheim’s Department of Material Analytical Sciences, spoke with PharmTech at AAPS PharmSci 360 to explain how tabletability prediction can be improved for roller-compacted formulations.
|Articles|February 19, 2014
Equipment and Processing Report
- Equipment and Processing Report-02-19-2014
- Volume 0
- Issue 0
Schreiner MediPharm Introduces SecuMed Labeling System
A combination of overt and covert features protects against counterfeiting.
Schreiner MediPharm’s SecuMed pharmaceutical labeling system offers authentication and protection against counterfeiting in a multi-step security concept. The SecuMed labeling system can be customized according to the specific requirements of pharmaceutical manufacturers. The labels can integrate a specific mix of overt, covert, and machine-readable security features. Options include complex holograms, ShiftSecure color-shifting ink, thermo-reactive print (in which colors change at various temperatures), and a covert feature known as LaserSecure, which involves invisible, machine-readable security pigments that can be integrated into all graphic elements and colors. The company will introduce the SecuMed labeling system to the North American market at INTERPHEX 2014.
Source:
Articles in this issue
over 12 years ago
Complying with Revised USP Chapters on Weighingover 12 years ago
Developments in Producing MicrospheresRelated to this article
This week on PharmTech.com, experts discussed E&L suitability standards, rare disease treatment development, sourcing ingredient suppliers, the use of AI in quality control, and more.
Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.
Mahmood Majeed, ZS, explains why measurable AI outcomes in pharma supply chain and manufacturing jumped from 29% to 53%, and how GMP limits and GxP validation shape adoption.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Ravi Kiran Kaja, PhD, USP, explains what harmonization of extractables and leachables standards looks like in practice.
Nine duloxetine recalls since 2024 show why generic drug manufacturers need route-level nitrosamine risk assessment, not end-product testing alone.
Ravi Kiran Kaja, PhD, explains how USP’s industry-wide initiative aims to build confidence in trace-level extractables and leachables results.
Trending on Pharmaceutical Technology
1
From URS to Acceptance Evidence: Defining and Testing Interfaces in Pen Injector Assembly
2
AAPS PharmSci 360 2026: IND-Enabling Studies vs Animal Data
3
PharmTech Weekly Roundup—October 23, 2026: CMC Considerations, Rare Disease Development, Standards Harmonization
4
Formulation Risk Needs One Accountable Owner: AAPS PharmSci 360 2026
5